Efficacy and safety of stereotactic body radiation therapy in treatment of patients with unresectable cholangiocarcinoma

Xiaofang ZHAO; Aimin ZHANG; Wengang LI; Jing SUN; Xiaoyun CHANG; Tao ZHANG; Weiping HE; Xuezhang DUAN

doi:10.3969/j.issn.1001-5256.2023.11.021

Volume 39 Issue 11

Nov. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(11): 2657-2662

PDF( 672 KB)

Efficacy and safety of stereotactic body radiation therapy in treatment of patients with unresectable cholangiocarcinoma

DOI: 10.3969/j.issn.1001-5256.2023.11.021

1.
Chinese PLA Medical College，Beijing 100039，China
2.
Department of Oncology and Radiotherapy，The Fifth Medical Center of Chinese PLA General Hospital，Beijing 100039，China

Research funding:

National Natural Science Foundation of China (81972856)

More Information

Corresponding author: DUAN Xuezhang， duanxuezhang2006@163.com （ORCID： 0000-0002-1941-9317）
Received Date: 2023-01-02
Accepted Date: 2023-04-11
Published Date: 2023-11-28

Abstract

Abstract

Objective To investigate the survival and adverse reactions of patients with unresectable cholangiocarcinoma after stereotactic body radiation therapy （SBRT）. Methods A total of 27 patients with unresectable solitary cholangiocarcinoma without metastasis who underwent SBRT in The Fifth Medical Center of Chinese PLA General Hospital from February 2012 to July 2020 were enrolled. The prescribed dose to planning target volume was 42-60 Gy in 5-8 fractions， with 5-11 Gy/fraction. Among these patients， five patients were also treated with chemotherapy and transcatheter arterial chemoembolization. The 6-， 12-， 18-， and 24-month overall survival （OS） rates， progression-free survival （PFS） rates， and local control （LC） rates were used as the assessment indices for treatment outcome； Common Terminology Criteria for Adverse Events v.4.03 was used to evaluate adverse reactions； the Kaplan-Meier method was used to calculate OS， PFS， and LC rates. Results The median follow-up time was 17 months. For all 27 patients， the 6-， 12-， 18-， and 24-month OS rates were 100%， 88%， 57.5%， and 47.9%， respectively； the 6-， 12-， 18-， and 24-month PFS rates were 74.1%， 58.6%， 47.9%， and 35.9%， respectively； the 6-， 12-， 18-， and 24-month LC rates were 96.3%， 91.9%， 84.8%， and 76.4%， respectively. No grade 3 or above toxic reactions were observed. Five patients were diagnosed with radiation-induced liver injury， but there was no death due to radiation-induced liver injury. Conclusion SBRT is safe and effective in the treatment of unresectable cholangiocarcinoma， with relatively high survival rate， PFS rate， and LC rate and low toxicity， and therefore， SBRT can be used as an alternative treatment method for patients with cholangiocarcinoma who are not candidates for surgery.
- Cholangiocarcinoma,
- Radiosurgery,
- Treatment Outcome

FullText(HTML)

References(29)

References

[1]	BERTUCCIO P, MALVEZZI M, CARIOLI G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma[J]. J Hepatol, 2019, 71( 1): 104- 114. DOI: 10.1016/j.jhep.2019.03.013.
[2]	BANALES JM, MARIN J, LAMARCA A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management[J]. Nat Rev Gastroenterol Hepatol, 2020, 17( 9): 557- 588. DOI: 10.1038/s41575-020-0310-z.
[3]	HEWITT DB, BROWN ZJ, PAWLIK TM. Current perspectives on the surgical management of perihilar cholangiocarcinoma[J]. Cancers(Basel), 2022, 14( 9): 2208. DOI: 10.3390/cancers14092208.
[4]	BRIDGEWATER JA, GOODMAN KA, KALYAN A, et al. Biliary tract cancer: Epidemiology, radiotherapy, and molecular profiling[J]. Am Soc Clin Oncol Educ Book, 2016, 35: e194- e203. DOI: 10.1200/EDBK_160831.
[5]	BENAVIDES M, ANTÓN A, GALLEGO J, et al. Biliary tract cancers: SEOM clinical guidelines[J]. Clin Transl Oncol, 2015, 17( 12): 982- 987. DOI: 10.1007/s12094-015-1436-2.
[6]	SAHA SK, ZHU AX, FUCHS CS, et al. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise[J]. Oncologist, 2016, 21( 5): 594- 599. DOI: 10.1634/theoncologist.2015-0446.
[7]	NIU YJ, ZHA Y, LI SJ, et al. Analysis on prognosis related factors of patients with cholangiocarcinoma after radical resection and establishment of survival prediction model[J]. J Jilin Univ(Med Edit), 2022, 48( 4): 979- 987. DOI: 10.13481/j.1671-587X.2022041. 牛英杰, 查勇, 李思嘉, 等. 胆管癌根治性切除术后患者预后相关因素分析和生存预测模型构建[J]. 吉林大学学报(医学版), 2022, 48( 4): 979- 987. DOI: 10.13481/j.1671-587X.20220418.
[8]	KHAN SA, DAVIDSON BR, GOLDIN RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update[J]. Gut, 2012, 61( 12): 1657- 1669. DOI: 10.1136/gutjnl-2011-301748.
[9]	KOZAK MM, TOESCA D, VON EYBEN R, et al. Stereotactic body radiation therapy for cholangiocarcinoma: optimizing locoregional control with elective nodal irradiation[J]. Adv Radiat Oncol, 2020, 5( 1): 77- 84. DOI: 10.1016/j.adro.2019.08.003.
[10]	FRAKULLI R, BUWENGE M, MACCHIA G, et al. Stereotactic body radiation therapy in cholangiocarcinoma: a systematic review[J]. Br J Radiol, 2019, 92( 1097): 20180688. DOI: 10.1259/bjr.20180688.
[11]	RAY CE EDWARDS Jr,, MITH MT, et al. Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma[J]. J Vasc Interv Radiol, 2013, 24( 8): 1218- 1226. DOI: 10.1016/j.jvir.2013.03.019.
[12]	KOAY EJ, ODISIO BC, JAVLE M, et al. Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments?[J]. Hepatobiliary Surg Nutr, 2017, 6( 2): 105- 116. DOI: 10.21037/hbsn.2017.01.16.
[13]	CRANE CH, MACDONALD KO, VAUTHEY JN, et al. Limitations of conventional doses of chemoradiation for unresectable biliary cancer[J]. Int J Radiat Oncol Biol Phys, 2002, 53( 4): 969- 974. DOI: 10.1016/s0360-3016(02)02845-6.
[14]	BUJOLD A, MASSEY CA, KIM JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma[J]. J Clin Oncol, 2013, 31( 13): 1631- 1639. DOI: 10.1200/JCO.2012.44.1659.
[15]	MAHADEVAN A, MIKSAD R, GOLDSTEIN M, et al. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 81( 4): e615-622. DOI: 10.1016/j.ijrobp.2011.04.045.
[16]	MAHADEVAN A, JAIN S, GOLDSTEIN M, et al. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer[J]. Int J Radiat Oncol Biol Phys, 2010, 78( 3): 735- 742. DOI: 10.1016/j.ijrobp.2009.08.046.
[17]	SUN J, WANG Q, HONG ZX, et al. Stereotactic body radiotherapy versus hepatic resection for hepatocellular carcinoma(≤5 cm): a propensity score analysis[J]. Hepatol Int, 2020, 14( 5): 788- 797. DOI: 10.1007/s12072-020-10088-0.
[18]	BISELLO S, CAMILLETTI AC, BERTINI F, et al. Stereotactic radiotherapy in intrahepatic cholangiocarcinoma: A systematic review[J]. Mol Clin Oncol, 2021, 15( 2): 152. DOI: 10.3892/mco.2021.2314.
[19]	KOAY EJ, OWEN D, DAS P. Radiation-induced liver disease and modern radiotherapy[J]. Semin Radiat Oncol, 2018, 28( 4): 321- 331. DOI: 10.1016/j.semradonc.2018.06.007.
[20]	DEOLIVEIRA ML, CUNNINGHAM SC, CAMERON JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution[J]. Ann Surg, 2007, 245( 5): 755- 762. DOI: 10.1097/01.sla.0000251366.62632.d3.
[21]	Expert Group of the State Key Project on Infectious Diseaseson‘Novel Strategies of Comprehensive and IndividualizdSurgical Treatment of Viral Hepatitis-related Liver Cancer’ from the Ministry of Science and Technology of China. Chinese expert consensus on the surgical management ofintrahepatic cholangiocarcinoma(2020 edition)[J]. Chin J Dig Surg, 2021, 20( 1): 1- 15. DOI: 10.3760/cma.j.cn115610-20201211-00777. 科技部传染病防治重大专项课题“病毒性肝炎相关肝癌外科综合治疗的个体化和新策略研究”专家组. 肝内胆管癌外科治疗中国专家共识(2020版)[J]. 中华消化外科杂志, 2021, 20( 1): 1- 15. DOI: 10.3760/cma.j.cn115610-20201211-00777.
[22]	REN B, GUO Q, YANG Y, et al. A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma[J]. Radiat Oncol, 2020, 15( 1): 15. DOI: 10.1186/s13014-020-1459-x.
[23]	HONG TS, WO JY, YEAP BY, et al. Multi-institutional phase Ⅱ study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. J Clin Oncol, 2016, 34( 5): 460- 468. DOI: 10.1200/JCO.2015.64.2710.
[24]	POLISTINA FA, GUGLIELMI R, BAIOCCHI C, et al. Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience[J]. Radiother Oncol, 2011, 99( 2): 120- 123. DOI: 10.1016/j.radonc.2011.05.016.
[25]	PARK SS, DONG H, LIU X, et al. PD-1 restrains radiotherapy-induced abscopal effect[J]. Cancer Immunol Res, 2015, 3( 6): 610- 619. DOI: 10.1158/2326-6066.CIR-14-0138.
[26]	POSTOW MA, CALLAHAN MK, BARKER CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma[J]. N Engl J Med, 2012, 366( 10): 925- 931. DOI: 10.1056/NEJMoa1112824.
[27]	DENG L, LIANG H, BURNETTE B, et al. Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression[J]. Oncoimmunology, 2014, 3: e28499. DOI: 10.4161/onci.28499.
[28]	KREIDIEH M, ZEIDAN YH, SHAMSEDDINE A. The combination of stereotactic body radiation therapy and immunotherapy in primary liver tumors[J]. J Oncol, 2019, 2019: 4304817. DOI: 10.1155/2019/4304817.
[29]	BAO G, LIU H, MA Y, et al. The clinical efficacy and safety of different biliary drainages in malignant obstructive jaundice treatment[J]. Am J Transl Res, 2021, 13( 6): 7400- 7405.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(3) / Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (169) PDF downloads(16)

Efficacy and safety of stereotactic body radiation therapy in treatment of patients with unresectable cholangiocarcinoma

DOI: 10.3969/j.issn.1001-5256.2023.11.021

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Efficacy and safety of stereotactic body radiation therapy in treatment of patients with unresectable cholangiocarcinoma

DOI: 10.3969/j.issn.1001-5256.2023.11.021

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content